Telix Appoints Darren Patti, Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

29th March 2021 – Corporate Spotlight | Darren Patti joins Telix as Chief Operating Officer, Telix Pharmaceuticals (US) Inc.

Telix is delighted to announce the appointment of Darren Patti as Chief Operating Officer, Telix Pharmaceuticals US (Inc).

Darren brings with him over 15 years’ experience in radiopharmacy network management and operations, including new radiopharmaceuticals implementation and compliance.

Most recently, Darren served as Vice President of Operations at Sofie Biosciences where he led the operationalisation of the Sofie-Lantheus PSMA PET imaging program.

Darren will lead Telix’s operations in the US, with his initial focus being to support the commercial team in preparation for the US launch of Telix’s lead product Illuccix® for prostate cancer imaging.

On joining Telix, Darren stated, “It gives me great pleasure to join the Telix team, where I am excited to use my experience gained in commercialising PSMA agents. Coupled with an advanced pipeline and go-to-market strategy, I am thrilled to be joining a winning team poised to deliver products that improve patient outcomes.”

We welcome Darren to the Telix team, as we work to deliver on our mission to help patients with cancer live longer, better quality lives.

To return to our home page please click here.

Illuccix® does not have marketing authorisation in any jurisdiction.